A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). (Q34453644)

2 August 2017

A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). (English)

1 reference

Adaptive radiation therapy

2 August 2017

0 references

0 references

1 reference

Minesh P Mehta

11

0 references

author name string

Brian M Alexander

1

1 reference

2 August 2017

Meihua Wang

2

1 reference

2 August 2017

W K Alfred Yung

3

1 reference

2 August 2017

Howard A Fine

4

1 reference

2 August 2017

Bernadine A Donahue

5

1 reference

2 August 2017

Ivo W Tremont

6

1 reference

2 August 2017

Ray S Richards

7

1 reference

2 August 2017

Kevin J Kerlin

8

1 reference

2 August 2017

Alan C Hartford

9

1 reference

2 August 2017

Walter J Curran

10

1 reference

2 August 2017

20 October 2012

1 reference

Journal of Neuro-Oncology

2 August 2017

1 reference

2 August 2017

111

1 reference

2 August 2017

1

1 reference

2 August 2017

33-39

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-012-0987-0

2 August 2017

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Sample size considerations for studies comparing survival curves using historical controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Angiogenesis inhibitors: current strategies and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Response assessment in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0987-0

Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23086432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The 2007 WHO classification of tumours of the central nervous system

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23086432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23086432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-012-0987-0

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference